Appointment of Director

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                            Appointment of Director                            

Bioventix plc (ISDX: BVXP) is delighted to announce the appointment of Nick
McCooke as a Non-Executive Director.

Mr. McCooke has worked in the biotech industry for over 25 years and is now an
independent consultant providing operational, strategic and commercial advice
and hands-on support to biotech companies. He was the founding Chief Executive
Officer of Solexa, a Cambridge University spin-out where he built the team that
invented and developed Next Generation DNA Sequencing. More recently he was CEO
of the Belgian company Pronota, which is translating novel protein biomarkers
into diagnostics. He has an MBA from the London Business School.

"We are delighted to welcome Nick McCooke to Bioventix", said Peter Harrison.
"His experience in building successful biotech companies is well established
and his appointment is a welcome addition at this stage of Bioventix's
development".

Further information on Nicholas McCooke:

Director/partner positions currently  Director/partner positions held in   
held:                                 the past 5 years:                    
                                                                           
none                                  Oxford Cancer Biomarkers Limited     

For further information please contact:

Bioventix plc  
Peter Harrison           Chief Executive Officer   Tel: [phone]       

finnCap Ltd     
Geoff Nash/Simon Hicks   Corporate Finance         Tel: [phone]                                  
Steve Norcross           Corporate Broking                                                    

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares (BVXP)
were admitted to trading on PLUS-SX in April 2010.